To compare a benefit of chemiotherapeutic protocols Docetaxel with Tarceva molecular therapy in advanced or metastatic non-small cell lung cancer (NSCLC). Primary endpoint-OS (Overall survival), Toxicity, Secondary endpoint-Quality of life. Patients and methods: In this retrospective and -prospective study a total of 63 patients (two groups-30+33 patients) were analysed and treated for advanced or metastatic NSCLC during the period 2008-2010. One group was treated with molecular therapy Tarceva oral, and the other group was treated with chemiotherapy Docetaxel monotherapy every three weeks. The chemotherapy was administered intravenously. Monitoring parameters included overall survival and toxicity. Results: Statistical differencet was registered in histology type, total toxicity and total survival. Adenocarcinom occured as a more often pathohistologic type in both groups of patients (Tarceva 57, 6% vs Docetaxel 83, 3%). The chemiotherapeutic protocol, Docetaxel monotherapy, demonstrated higher total toxicity than Tarceva molecular therapy (hematological toxicity grade II 69. 0 % Docetaxel vs 12. 5 % Tarceva). Tarceva molecular therapy demonstrated longer overall survival (OS) than Docetaxel (Tarceva 26, 4 months vs Docetaxel 15, 5 months). Conclusion: In this investigation of two groups of patients the molecular therapy Tarceva was showed better efficiency and toxicity profile. Preferred regimen could be molecular therapy Tarceva.
INTRODUCTION
Lung cancer occurs in the bronchial wall and lung cells and it develops over a period of many years. Numerous studies and meta-analyses have shown that chemotherapy is only one modality of treatment of these patients (1) . Generally, this type of treatment is not curative and must take into account the quality of life of these patients (2) . According to the data of the Surveillance, Epidemiology and End Results SEER Program NCI, USA, 2003. lung cancer was on the second place of morbidity, and also on the first place of mortality among malignant diseases in both genders (3) . Every year 1, 5 milion new patients with lung cancer are registered worldwide (4) . The major risk factor is smoking which is responsible for ninety percent of lung cancer cases. A person smoking pack of cigarettes has twenty times higher risk for lung cancer (5) .
Cispaltin and Carboplatin are two powerfull medicines in the NSCLC therapy (6, 7) . However, the biggest discovery was of the first generation drugs: Paclitaxel, Docetaxel, Pemetrexed, Irinotecan, Topotecan, Vinorelbin and Gemcitabin which showed the biggest efficiency in the treatment of such patients (8, 9, 10, 11, 12, 13, 14) .
AIM
The aim of this study was to compare two different protocols and deter-analysis of Chemotherapy and molecular Therapy efficiency in advanced or metastatic Non-small Cell Lung Cancer mine which of them has higher efficacy and less toxicity.
pATIeNTS AND MeTHODS
In this retrospective/prospective study we included a total of 63 patients with advanced or metastatic NSCLC/ III B or IV/ divided in two groups in the period 2008-2010. One group of 33 patients was analysed and treated with Tarceva molecular monotherapy. In the same period, the other group of 30 patients were treated with chemiotherapeutic protocol Docetaxel monotherapy. Therefore, patients with locally advanced or metastatic NSCLC were treated with two different protocols in two different medical centers.
The treatment plan was that the first group of patients received Tarceva 150 mg one tablet daily, one hour before or two hours after meal until progression or until serious toxicity . The second group received Docetaxel 75 mg/ m 2 chemotherapy intravenously every three weeks (with pre and post medication of Dexamethasone).
We analyzed total toxicity and total survival in all patients.
Toxicity was evaluated as hematological (CBC, DKS-anaemia, trombocytopenia, leucopenia grade I-IV), as non-hematological (neurotoxicity, skin changes-alopetia grade I-IV, nail changes, rush, bule, eruptions, gastrointestinal perforations-vomiting, diarrhoea grade I-IV, pain in the eye, keratoconjuctivitis sicca).
Therapeutic response was evaluated by repeating the initial diagnostic procedures after every 2 nd Cycle (X-ray, CTComputed Tomography of the thorax, ultrasound of abdomen).
Survival was calculated from the date of the beginning of disease until the date of letal outcome of any cause or until the date of the last control examination. Statistical methods that were used included X 2 test and Log rank test.
ReSULTS
A total of 63 patients divided into two groups were analysed. The first group: 33 patients treated with Tarceva molecular monotherapy.
The second group: 30 patients treated with chemotherapy, Docetaxel monotherapy.
In the first group of patients who received Tarceva 20 patients (60. 6%) were male, and 13 patients (39. 4%) were female.
In the second group of patients who received Docetaxel 25 patients (83. 3%) were male and 5 patients (16.7%) were female, without statistically significant differences The median age in the first group was 57 years, and in the second group it was 60, also without statistically significant differences.
The general status of patients assessed by the ECOG scale (Easter Cooperative Oncology Group) showed no statistically significant difference in the two groups.
In the first group on the Tarceva ECOG 0 was noted in 4 patients (12. 1%) and in the second group on the Docetaxel 2 patients (6. 9%). In the first group on the Tarceva 22 patients (66. 7%) had ECOG 1 and in the second group on the Docetaxel 23 patients (79. 3%). In the first group on the Tarceva 7 patients (21. 2%) had ECOG 2 and in the second group on the Docetaxel 4 patients (13. 8%) (Figure 2 ). Statistically significant differences were registered in the histological type of carcinoma. Adenocarcinoma was the patohistological type that occurred more often in both groups. In the first group adenocarcinoma was registered in 57. 6 % patients and in the second group in 83. 3 %. Planocelular carcinoma was registered in the first group in 42. 4 % patients and in the second group in 13. 3 %.
Gigantocellular carcinoma was registered only in the second group in 3. 3 % patients (Figure 3) . Also, statistically significant differences were registered in hematological toxicity. Hematological toxicity grade I was noted in 7 patients (87. 5 %) on the Tarceva and in the second group on Docetaxel in 1 patient (3. 4 %). Hematological toxicity grade II occurred in 1 patient (12. 5 %) on the Tarceva and in the second group on Docetaxel 20 patients (69. 0 %).
None of the patients on the Tarceva had hematological toxicity grade III and in the second group on Docetaxel it was noted in 8 patients (27. 6 %) (Figure 4 ).
Otherwise, Tarceva demonstrated less toxicity than Docetaxel. Statistically significant differences were registered in non-hematological toxicity.
15 patients on the Tarceva had one non-hematological toxicity and 29 patients on Docetaxel.
Non-hematological toxicity grade I occurred in 13 patients on the Tarceva and in the second group on Docetaxel none of the patients had it. Non-hematological toxicity grade II was noted in 2 patients on the Tarceva and in the second group on Docetaxel no patients had analysis of Chemotherapy and molecular Therapy efficiency in advanced or metastatic Non-small Cell Lung Cancer it. Non-hematological toxicity grade III occurred in 3 patients on the Tarceva and none from the second group on Docetaxel.
None of the patients on the Tarceva had non-hematological toxicity grade IV and in the second group on the Docetaxel it was noted in 1 patient (Figure 5) .
Non-hematological toxicities were described and expected and do not lead to significant exacerbation of the general status as in patients receiving Docetaxel.
Statistically significant differences were also registered in overall survival between the two protocols. Overall survival is divided in two categories: from the start of the disease, and from the start of therapy.
Overall survival from the start of disease in the group treated with Tarceva was 26. 4 months and in the group on Docetaxel it was 15. 5 months (Figure 6 ).
Overall survival from the start of therapy in the group treated with Tarceva was 15 months and in a the group on Docetaxel it was 6. 8 months. Therefore, Tarceva proved to be superior to Docetaxel (Figure 7 ).
DISCUSSION AND CONCLUSION
The hemotherapeutics in the treatment of NSCLC are divided into three generations.
The first generation consists of Ifosfamid, Mitomycin, Vinblastin and Vindesin. Their application has led to improvements in quality of life of these patients.
The second generation consists of Cisplatin and Carboplatin which achieve excellent results in the treatment of NSCLC for that period (6, 7, 8, 9, 10, 11, 12, 13, 14, 15) .
The third generation consists of Paclitaxel, Docetaxel, Irinotecan, Topotecan, Vinorelbin and Gemcitabin (8, 9, 10, 11, 12, 13, 14) . The optimal number of hemotherapeutic agents was analysed in the several clinical studies and two meta-analyses. The conclusion was that the doublets are the gold standard in the treatment patients of NSCLC (15) . In this study statistically significant differences were registered in pathohistological type of tumours, total toxicity and total survival. Adenocarcinoma occurred more often as a pathohistologiocal type in both groups of patients. In the first group treated with Tarceva adenocarcinoma was registered in 57. 6 % of patients and in the second group on Docetaxel in 83. 3 % patients. Tarceva molecular monotherapy has shown less toxicity than Docetaxel.
Hematoogical toxicity grade II was noted in 12. 5 % of patients on Tarceva and 69.0 % on Docetaxel.
More non-hematological toxicity was registered in patients on Tarceva than on Docetaxel. Non-hematological toxicity grade I occurred in 39. 4 % of patients on Tarceva but that toxicity was described and expected and does not lead to significant exacerbation of the general status of patients like in those receiving Docetaxel.
In addition this study registered statistically significant differences in total survival between Tarceva and Docetaxel. Again, Tarceva has shown superiority over Docetaxel. The total survival in the first group on Tarceva was 26. 4 months and in the second group on Docetaxel it was 15. 5 months.
The quality of life is a very important fact. The quality of life is a very important fact for patients with NSCLC. Therefore, in addition to efficiency we took into account the toxicity of the therapy. In respect to these two criteria a prefferred protocol could be the Tarceva molecular therapy. 
